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IMPORTANCE Health care spending in the United States is a major concern and is higher than
in other high-income countries, but there is little evidence that efforts to reform US health
care delivery have had a meaningful influence on controlling health care spending and costs.
OBJECTIVE To compare potential drivers of spending, such as structural capacity and
utilization, in the United States with those of 10 of the highest-income countries (United
Kingdom, Canada, Germany, Australia, Japan, Sweden, France, the Netherlands, Switzerland,
and Denmark) to gain insight into what the United States can learn from these nations.
EVIDENCE Analysis of data primarily from 2013-2016 from key international organizations
including the Organisation for Economic Co-operation and Development (OECD), comparing
underlying differences in structural features, types of health care and social spending, and
performance between the United States and 10 high-income countries. When data were not
available for a given country or more accurate country-level estimates were available from
sources other than the OECD, country-specific data sources were used.
FINDINGS In 2016, the US spent 17.8% of its gross domestic product on health care, and
spending in the other countries ranged from 9.6% (Australia) to 12.4% (Switzerland). The
proportion of the population with health insurance was 90% in the US, lower than the other
countries (range, 99%-100%), and the US had the highest proportion of private health
insurance (55.3%). For some determinants of health such as smoking, the US ranked second
lowest of the countries (11.4% of the US population 15 years smokes daily; mean of all 11
countries, 16.6%), but the US had the highest percentage of adults who were overweight or
obese at 70.1% (range for other countries, 23.8%-63.4%; mean of all 11 countries, 55.6%).
Life expectancy in the US was the lowest of the 11 countries at 78.8 years (range for other
countries, 80.7-83.9 years; mean of all 11 countries, 81.7 years), and infant mortality was the
highest (5.8 deaths per 1000 live births in the US; 3.6 per 1000 for all 11 countries). The US
did not differ substantially from the other countries in physician workforce (2.6 physicians per
1000; 43% primary care physicians), or nursing workforce (11.1 nurses per 1000). The US had
comparable numbers of hospital beds (2.8 per 1000) but higher utilization of magnetic
resonance imaging (118 per 1000) and computed tomography (245 per 1000) vs other
countries. The US had similar rates of utilization (US discharges per 100 000 were 192 for
acute myocardial infarction, 365 for pneumonia, 230 for chronic obstructive pulmonary
disease; procedures per 100 000 were 204 for hip replacement, 226 for knee replacement,
and 79 for coronary artery bypass graft surgery). Administrative costs of care (activities
relating to planning, regulating, and managing health systems and services) accounted for 8%
in the US vs a range of 1% to 3% in the other countries. For pharmaceutical costs, spending
per capita was $1443 in the US vs a range of $466 to $939 in other countries. Salaries of
physicians and nurses were higher in the US; for example, generalist physicians salaries were
$218 173 in the US compared with a range of $86 607 to $154 126 in the other countries.
CONCLUSIONS AND RELEVANCE The United States spent approximately twice as much as
other high-income countries on medical care, yet utilization rates in the United States were
largely similar to those in other nations. Prices of labor and goods, including pharmaceuticals,
and administrative costs appeared to be the major drivers of the difference in overall cost
between the United States and other high-income countries. As patients, physicians, policy
makers, and legislators actively debate the future of the US health system, data such as these
are needed to inform policy decisions.
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T he United States spends more per capita on health carethan any other nation, substantially outpacing even othervery high-income countries.1,2 However, despite its
higher spending, the United States performs poorly in areas such
as health care coverage and health outcomes.3-5 Higher spending
without commensurate improved health outcomes at the popula-
tion level has been a strong impetus for health care reform in the
United States.6
Although it is well known that the United States spends
more on health care than other countries, less is known about
what explains these differences. The consensus has been that
the US fee-for-service system is a primary factor,7 leading to
fragmentation, overuse, and
an underinvestment in social
determinants of health,8-10
dr iv ing high uti l izat ion of
health care services and poor
outcomes. Older studies have
found that the United States
may underinve st in socia l
services,11 although other data
suggest that higher prices
in the United States, especially
for pharmaceuticals, may be
a contributor to spending dif-
ferences.12,13 One study sug-
gested that increasing rates of outpatient spending and remu-
neration of clinicians is a major contributor to the cost difference
between the United States and other countries.14 Given that
other high-income countries are able to spend less and achieve
better health outcomes, a more nuanced, data-driven under-
standing of all aspects of health care cost are needed to assist in
reform of the US health care system.
The Organisation for Economic Co-operation and Develop-
ment (OECD) and the Commonwealth Fund have recently col-
lected and made available increasingly comparable data on inputs
and performance of the health care systems across high-income
countries. Using these and related data, we compared perfor-
mance of the United States with 10 other high-income countries on
key metrics that underpin health care spending. By examining
granular data, we sought to understand why US health care costs
are so much higher and where policy makers might target their
efforts to encourage a more efficient system.
Methods
Selection of Comparison Countries
Ten high-income countries were selected for comparison. These
countries were chosen because they were among the highest-
income countries in the world, had relatively high health care
spending, and had populations with similar demographic character-
istics that have similar burdens of illness.3,15 Based on these criteria,
the United Kingdom (consisting of England, Scotland, Wales, and
Northern Ireland), Canada, Germany, Australia, Japan, Sweden,
France, Denmark, the Netherlands, and Switzerland were chosen
for comparison. These 10 selected countries represent different
geographic areas and diverse health system structures.
Conceptual Framework and Indicator Selection
To better understand the higher US health care costs relative to
other high-income countries, a range of outcomes were explored.
We first analyzed comparative data on general health system
spending, including spending by function. Next, comparative
inputs, including labor costs and structural capacity (which,
aside from contributing to direct costs, may also influence mainte-
nance costs or influence the price to use equipment) were ex-
amined. Because many of the leading explanations relating to
higher health care costs involve the transformation of health care
dollars to health care outcomes,16 we extended the analysis to
examine a range of intermediate outputs—namely, access, utiliza-
tion (inpatient, outpatient, major procedures), pharmaceutical
spending and utilization, patient experience, and quality of care—as
well as valued health system outcomes, such as population health.
To provide a broader context of overall factors that can contribute
to differences in health care spending, we also examined social
spending, as well as demographic differences, risk factors, and
prevalence of disease. In line with previous international compari-
sons, the health care system included all groups whose primary
intent is to improve health.5,17
This approach resulted in the presentation of a total of 98 indi-
cators across 7 domains: (1) general spending; (2) population
health; (3) structural capacity; (4) utilization; (5) pharmaceuticals;
(6) access and quality; and (7) equity. In each domain, measures
were selected that were available across the majority of the coun-
tries in the analysis. We were unable to find comparable pricing
data for most areas, such as for diagnostic procedures and treat-
ments, except for workforce remuneration and pharmaceuticals.
In the area of quality, the focus was on indicators that captured
quality of prevention, primary care, and inpatient care across the
areas of appropriateness, effectiveness, experience, and safety. In
the area of access to care, variations related to financial costs as
well as waiting times were explored. In addition, reflecting equity,
variations related to service availability, quality of care, and cost
were assessed.
Data Sources
Data were extracted from a range of databases compiled by inter-
national organizations, with the majority coming from the OECD.
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Key Points
Question Why is health care spending in the United States so
much greater than in other high-income countries?
Findings In 2016, the United States spent nearly twice as much as
10 high-income countries on medical care and performed less well
on many population health outcomes. Contrary to some
explanations for high spending, social spending and health care
utilization in the United States did not differ substantially from
other high-income nations. Prices of labor and goods, including
pharmaceuticals and devices, and administrative costs appeared
to be the main drivers of the differences in spending.
Meaning Efforts targeting utilization alone are unlikely to reduce
the growth in health care spending in the United States; a more
concerted effort to reduce prices and administrative costs
is likely needed.
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Data on structural equipment, workforce, utilization, pharmaceuti-
cal spending, access, and quality were accessed from OECD.stat
and the OECD 2015 Health Care at a Glance report. Additional
data on health spending, health system, and country characteris-
tics were obtained from the World Bank International Bank for
Reconstruction and Development–International Development
Association database and the 2016 OECD Health Systems Charac-
teristics Survey.
Data on retail pharmaceutical spending per capita were
obtained from the OECD for all countries. Data on total pharmaceu-
tical spending per capita were obtained from Intercontinental
Marketing Services or the International Federation of Pharmaceuti-
cal Manufacturers and Associations. Pharmaceutical data on
country-level output of new chemical entities was taken from
Daemmrich.18 Population perceptions of the health system and
select access measures were obtained from the 2016 Common-
wealth Fund Survey of Consumers.15
All data on per capita spending, gross domestic product (GDP),
and remuneration were translated into US dollar equivalents, with
exchange rates based on purchasing power parities of national cur-
rencies. Remuneration data were then converted to 2017 dollars
using the US Consumer Price Index in line with Laugesen and
Glied.19 Data on health spending are presented by function of care
as a percentage of the country’s total spending on health consis-
tent with System of Health Accounts categorization, with adapta-
tions for outpatient spending to address issues of comparability
with the United States’ National Health Expenditure Accounts
(eTable 2 in Supplement 1). When OECD data were not available
for a given country or more accurate country-level estimates were
available, country-specific data sources were used. The focus was
on indicators from 2013 onward with an occasional exception. For
example, for the United States, data for the horizontal index, neo-
natal mortality by low birth weight, and antibiotic prescribing were
from 2009, 2004, and 2004, respectively.
Figure 1. Spending
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Health expenditure by function of care as a % of total national health expenditure

























GDP indicates gross domestic product; NA, not applicable. CHE indicates Switzerland; NLD, the Netherlands. See eTable 1 in Supplement 2 for data ordered by country.
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Supplement 1 includes tables that provide a breakdown of
sources and methods for the data reported herein. In these tables,
we note issues of comparability and timeliness for each indicator,
such as workforce. In figures describing data for each of the 7 do-
mains, a simple mean of the data for each indicator across all 11 coun-
tries is presented in the final column. Throughout the Results sec-
tion in the text, all comparative findings are presented descriptively.
Results
Demographic Characteristics and Health Care Spending
In 2016, the US population was significantly larger than all
comparison countries at 323 million (Figure 1 and eTable 1 in
Supplement 2). Japan had the next largest population with 127 mil-
lion. The US system also covered the second largest geographical
area (9 834 000 sq km), following Canada (9 985 000 sq km). The
other countries other than Australia had much smaller land mass.
In 2016, the United States spent 17.8% of its GDP on health care
(range of the other countries, 9.6%-12.4%; mean of all 11 countries,
11.5%) (Figure 1 and Figure 2) and had almost double the health
spending per capita (mean, $9403) compared with the other coun-
tries (range, $3377-$6808; mean of all 11 countries, $5419).
Although the United States spent more, the percentage of the
population with health insurance in the United States was 90%,
lower than in all of the other countries (range, 99%-100%).
All systems had relatively similar levels of public spending as a
percentage of GDP (defined as spending from government and/or
social or compulsory insurance funds), with the United States spend-
ing at about the mean level (8.3%) of all the countries, although, un-
like the other countries, this spending covered only about 37% of
the population. By expenditure as a function of care, the United
States spent only 19% of its health spending on inpatient care, which
excludes same-day hospital care. This proportion was less than that
of all other countries, with Australia (31%) and the Netherlands (32%)
spending the most (Figure 1). The United States spent a greater pro-
portion than the other countries on outpatient care (44% com-
pared with a mean of 31%) and governance and administration, which
includes activities relating to planning, regulating, and managing
health systems and services (8% compared with a mean of 3%).
Across the 11 countries, the United States had the lowest per-
centage of the population older than 65 years (14.5% compared with
a mean of 18.2%) and also had the highest rate of poverty, with 24%
of the population living below the poverty line, followed by Japan
(22%) and Canada (21%). The United States ranked below the mean
but was not an outlier with regard to total social spending (spend-
ing on old age, incapacity, labor market, education, family, and hous-
ing [Figure 3]) at 16.7% of GDP (compared with a mean of 19.4% of
GDP in all 11 countries). This reflected public social spending, which
was, at 11.3% of GDP, below the mean of all 11 countries (15.3% of
GDP). The United States ranked fourth with regard to private social
spending at 5.4% of GDP (compared with a mean of 4.1%) and was
similar to the United Kingdom (5.6%) and ranked behind
the Netherlands (7.1%) and Switzerland (6.0%), reflecting mostly
private pension payments.20
Insurance System Characteristics
The structural characteristics of the health care system are de-
tailed in the Table. Three countries, the United Kingdom, Sweden,
and Denmark, have national health care systems, whereas
Canada and Australia have regionally administered universal insur-
ance programs. Germany, France, the Netherlands, and Switzerland
have statutory/mandatory health insurance systems. Only the
United States has a voluntary, private employer-based and
individual-based system. All of the countries except the United
States have an automatic or compulsory enrollment process.
Private insurance as the primary form of insurance is highest in the
United States at 55.3%, followed by Germany at 10.8%. The major-
ity of the countries do not have private insurance as the primary
form of insurance.
Population Health
Among important determinants of health, the United States had the
highest percentage of overweight or obese adults (70.1% com-
pared with a mean of 55.6%) but had relatively low smoking rates
(11.4% of the population compared with a mean of 16.6%) (Figure 4
and eTable 2 in Supplement 2). The drinking rate (8.8 L per capita)
and unemployment rate (4.4%) in the United States are both
close to the mean values of all 11 countries at 9.1 L per capita and
5.4%, respectively.
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The United States consistently had the poorest population
health outcomes (Figure 4). The United States had the lowest life
expectancy (78.8 years compared with a mean of 81.7 years) and
the lowest health-adjusted life expectancy (69.1 years compared
with a mean of 72.0 years). The variability of life expectancy across
the United States (ranging from 81.3 years in Hawaii to 75 years in
Mississippi) (eTable 3 in Supplement 1) was similar to that of the life
expectancy across all countries in the study.
The United States had the highest infant mortality (5.8 deaths
per 1000 live births compared with a mean of 3.6), neonatal mor-
tality (4.0 deaths per 1000 live births compared with a mean of 2.6),
and maternal mortality (26.4 deaths per 100 000 live births com-
pared with a mean of 8.4) (Figure 4). The United States also had the
second highest percentage of infants with low birth weight (8.1%
compared with a mean of 6.6%). Japan had the highest low birth
weight (9.5%). When adjusting neonatal mortality to exclude deaths
of infants born weighing less than 1000 g, the United States ranked
fifth relative to the other countries, with 1.61 deaths per 1000 live
births, compared with a mean of 1.70 for all 11 countries.
Workforce and Structural Capacity
The physician workforce in the United States was lower than the
mean of all 11 countries at 2.6 per 1000 population compared with
3.3 per 1000 population (Figure 5 and eTable 3 in Supplement 2).
The proportion of US physicians who were primary care physicians
(43%) was the same as the mean of all 11 countries. Using a func-
tionality-based approach to identifying primary care physicians,
US general internists provided a significant amount of primary care,
whereas internists in Canada almost exclusively provided acute
hospital-based care (Figure 6). Compared with countries with
comparable data, mean remuneration of generalists, special-
ists, and nurses was higher in the United States. When adjusting
for purchasing power parity, the mean US remuneration for gener-
alists was $218 173, nearly double the mean remuneration in all 11
countries, which ranged from $86 607 in Sweden to $154 126 in
Germany. The remuneration for specialists was higher in the United
States at $316 000 compared with other countries, ranging from
$98 452 in Sweden to $202 291 in Australia). The remuneration of
nurses was also higher in the United States ($74 160) than in other
countries, where it ranged from $42 492 in France to $65 082 in the
Netherlands. The remuneration of health care professionals as a ra-
tio to the mean national wage was highest in the United States for
specialists (5.3 compared with a mean of 3.7), generalists (3.6 com-
pared with a mean of 2.7), and nurses (1.23 compared with
a mean of 1.1).
There was notable variation between countries in the supply of
medical equipment, such as magnetic resonance imaging (MRI) units,
computed tomography (CT) machines, and mammography ma-
chines. Japan had the highest number of MRI units and CT scanners
per population (approximately 52 and 107 per 1 million population, re-
spectively), and the United States had the second highest for MRI
(38 per 1 million population) and third highest for CT (41 per 1 million
population). The lowest per capita rate for both MRI units and CT scan-
ners was in the United Kingdom, with 7.2 MRI units and 9.5 CT scan-
ners per 1 million population. The United States had fewer hospital
beds per 1000 population (2.8) than Japan (13.2) and Germany (8.2)
and fewer long-term beds per 1000 population older than 65 years
(38.8) compared with the mean of the study countries (54.2).
Utilization
The United States’ utilization of health care services was similar
to the other countries (Figure 7 and eTable 4 in Supplement 2),
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Social spending is the provision by public (and private) institutions of benefits to
and financial contributions targeted at households and individuals to provide
support during circumstances that adversely affect their welfare, provided that
the provision of the benefits and financial contributions constitutes neither a
direct payment for a particular good or service nor an individual contract or
transfer. Such benefits can be cash transfers or can be direct (in-kind) provision
of goods and services. Main spending areas include old age, health, family,
incapacity, labor market, and housing (Organisation for Economic Co-operation
and Development). Private social spending is functionally the same as public
social spending but provided through a private mechanism. Social benefits
delivered through the private sector (not transfers between individuals) involve
an element of compulsion and/or interpersonal redistribution; for example,
through pooling of contributions and risk sharing. This may include old-age
pensions and support services for older adults, survivor benefits, disability and
sickness cash benefits, family support, unemployment benefits, housing
support (eg, rent subsidies), and other social policy areas excluding health
spending. Pensions constitute an important part of private social spending in
the United States and can be mandatory or voluntary. Independent,
out-of-pocket spending on social services is not included.
Clinical Review & Education Special Communication Health Care Spending in the United States and Other High-Income Countries
1028 JAMA March 13, 2018 Volume 319, Number 10 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Health Care Spending in the United States and Other High-Income Countries Special Communication Clinical Review & Education
jama.com (Reprinted) JAMA March 13, 2018 Volume 319, Number 10 1029
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a London School of Economics User  on 03/14/2018
except for imaging. The United States performed the second high-
est number of MRI scans and the highest number of CT scans (118
MRIs per 1000 population compared with a mean in all 11 countries
of 82 per 1000 population; 245 CTs per 1000 population com-
pared with a mean of 151 per 1000 population).
Annual hospital discharges in the United States, at 125 per 1000
population, were just below the middle of the distribution (ranging
from 84 per 1000 in Canada to 255 per 1000 in Germany, with a
mean of 150 per 1000 in all 11 countries) (Figure 8). Discharges for
common conditions in the United States such as acute myocardial
infarction (192 per 100 000 population compared with a mean of
190 per 100 000 population), pneumonia (365 per 100 000 popu-
lation compared with a mean of 352 per 100 000 population), and
chronic obstructive pulmonary disease (230 per 100 000 popula-
tion compared with a mean of 206 per 100 000 population) were
similar to the means of all 11 countries. For discharges for mental and
behavioral conditions, the United States was below the mean of all
11 countries (679 per 100 000 population compared with a mean
of 736 per 100 000 population) (Figure 7). Consultation levels in the
United States were below the mean at 4 visits per person per year
compared with a mean of 6.6 (Figure 8).
The United States had somewhat higher levels of some com-
mon surgical procedures, such as revascularization procedures (for
coronary artery bypass procedures, 79 per 100 000 population com-
pared with a mean of 54 per 100 000 population), knee replace-
ments (226 per 100 000 population compared with a mean of 163
per 100 000 population), cesarean deliveries (33 per 100 live births
compared with a mean of 25 per 100 live births), coronary angio-
plasties (248 per 100 000 population compared with a mean of 217
per 100 000 population), and cataract surgeries (1110 per 100 000
population compared with a mean of 971 per 100 000 popula-
tion). For a few procedures, the United States had comparable or
lower rates vs the other 10 countries, such as for hip replacements
(204 per 100 000 population compared with a mean in all 11 coun-
tries of 207 per 100 000 population).
Length of stay had less variation across countries with the ex-
ception of Japan, which had a mean all-cause length of stay of 16.9
days, far longer than in the other countries (Figure 8). The United
States had relatively fewer days in the hospital compared with the
mean for 3 different length-of-stay measures (all-cause hospitaliza-
tion, normal neonatal delivery hospitalization, and acute myocar-
dial infarction hospitalization) (Figure 7).
The United States had high levels of administrative burden; this
was notable in particular for administrative spending, for which the
United States was an outlier (8% of GDP spent on administration and
governance compared with a mean of 3% of GDP) (eTable 1 in
Supplement 1). Physicians in the United States also reported hav-
ing a higher level of administrative burden than the mean of all 11
countries in 3 areas; however, this burden was high in all insurance-
based systems. Fifty-four percent of surveyed physicians in the
United States identified time spent on administrative issues re-
lated to insurance or claims as a major problem, 33% reported that
Figure 4. Population Health
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NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands. See eTable 2 in Supplement 2 for data ordered by country.
a Patient self-reported data.
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“time spent on administrative issues related to reporting clinical or
quality data to government or other agencies is a major problem,”
and 16% reported having spent “a lot of time on paperwork or dis-
putes related to medical bills.”
Pharmaceuticals
Among the 11 countries, the United States had the highest pharma-
ceutical spending per capita at $1443, with Switzerland following at
$939 and a mean of $749 for all 11 countries (Figure 9 and eTable 5
in Supplement 2). Retail spending per capita was also highest in the
United States at $1026, representing about 71% of the total, which
was consistent with the group mean at 72% (Figure 9). For 4 phar-
maceuticals (Crestor, Lantus, Advair, and Humira) used for com-
mon conditions, the United States had higher prices than all other
countries; for 3 of these, the US price was more than double the
next highest price. With respect to a measure of innovation, the
United States and Switzerland had the highest number of new
chemical entities at 111 and 26, respectively. The United States
accounted for 57% of total global production of new chemical enti-
ties. No estimates were available for Canada, Australia, Sweden,
the Netherlands, and Denmark. The United States also had high
generic penetration at 84% of the total pharmaceutical market,
which was comparable with markets in the United Kingdom and
Germany. Australia and the Netherlands had low generic penetra-
tion at 30% and 17%, respectively. Despite having the highest rate
of generic penetration, the amount that the United States spent
on generic products as a percentage of total pharmaceutical spend-
ing was similar to other countries, suggesting that brand-name
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Workforce remuneration, US $
Beds
NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands.
See eTable 3 in Supplement 2 for data ordered by country. Generalist physicians
are defined as any practicing physician registered in his or her country as
a generalist physician or a specialist in the field of family medicine, pediatrics,
geriatrics, or internal medicine and excludes students, interns, and
nonpracticing physicians. Remuneration numbers may be an underestimate in
some countries (eg, Canada) because they do not account for practice expenses
for self-employed physicians. Japan is excluded from remuneration means with
the exception of nursing. Definitions of specialist and generalist physicians
in regard to remuneration were taken from the Organisation for Economic
Co-operation and Development.
a The number for Japan, 124 558, is a combined total of generalists and specialists.
b In 2016 constant prices at 2016 US dollar purchasing power parities.
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pharmaceuticals were largely responsible for high overall spending.
These countries have notably different ways in how they finance
pharmaceuticals; there is considerable variation in both the share
covered by private insurance and the percentage covered by pri-
vate out-of-pocket spending. The United States had high levels of
private spending (36% compared with a mean of 8%), although
similar to Canada (30%), and was below the mean for out-of-
pocket spending at 30% (compared with a mean of 36%). With
regard to antibiotic prescriptions, which are often considered a
measure of inappropriate treatment, the United States was above
the mean, with a defined daily dose (average maintenance dose
per day for a drug used for its main indication in adults) of 24 com-
pared with a mean of 20.2.
Access and Quality
Relative to comparison countries, US performance varied on qual-
ity and access measures (Figure 10 and eTable 6 in Supplement 2).
Of the other countries examined, the United States was the only one
in which a sizeable minority (approximately 10%) of individuals
lacked coverage for basic health care services (Figure 1). For the 3
access measures (ability to get same- or next-day care when sick,
2-month wait time to see a specialist, and adequate time spent with
regular physician) the United States generally performed better than
the other countries. In the United States, 51% were able to get same-
or next-day care compared with a mean of 57% in all 11 countries. In
the United States, 6% had a wait time of 2 months or more to see a
specialist compared with mean of 13% in all 11 countries. Waiting
times to see a specialist were longer for national health service
and single-payer systems (ie, percentage with wait times longer
than 2 months: Canada, 39%; United Kingdom, 19%; Sweden, 19%)
compared with insurance-based systems (Netherlands, 7%;
Switzerland, 9%; Germany, 3%; France, 4%), with a mean of 13%.
The United States ranked near the mean for patients reporting hav-
ing spent adequate time with their regular physician (81% com-
pared with a mean of 83% in all 11 countries).
The United States had relatively high screening rates for breast
cancer (81% compared with a mean of 67% in all 11 countries) but
lower rates of measles immunization (92% compared with a mean
of 94%) (Figure 10). The United States had considerably lower rates
of all 4 clinical outcome measures than the other countries. Thirty-
day mortality for ischemic stroke was 4.2 per 100 patients in the
United States compared with a mean of 7.9 per 100 patients in all 11
countries. For obstetric trauma without instrument, the United States
had 1.5 cases per 100 deliveries, whereas the mean was 2.3 per 100
deliveries in all 11 countries. The United States had high avoidable
hospitalizations for diabetes and asthma relative to comparison
countries (191.0 per 100 000 population compared with a mean of
125.6 per 100 000 population for diabetes, and 89.7 per 100 000
population compared with a mean of 42.4 per 100 000 popula-
tion for asthma). When accounting for disease prevalence, the rate
of US hospitalizations for diabetes was similar to that of other coun-
tries, although hospitalizations for asthma were highest in the United
States, closely followed by the United Kingdom. Relative to the other
countries, the US public reported the lowest satisfaction with their
health system, with only 19% reporting that the system works well.
US Disaggregated Data
When access and quality measures were disaggregated by payer,
the United States performed slightly worse for those covered by
Medicaid, but performance was uneven across insurance groups
(eTable 4 in Supplement 1). Nine percent of both privately insured
individuals and those insured by Medicaid reported a 2-month wait
time to see a specialist; this was lower than rates for Medicare
patients (11%) but higher than for uninsured individuals (8%). On
selected prevention measures, such as measles immunization, pri-
vately insured individuals had the highest rate of coverage at 95%,


























The total number of physicians, or 100%, differs for each country. Data are 2017
or closest available year. A functionality-based definition to identify primary
care was used to identify physicians as those who provide a set of activities
whose functions define the boundaries of primary care. This included chronic,
preventive, and acute care in both inpatient and outpatient settings irrespective
of disease: disease prevention, early detection and diagnosis, treatment and
management, care coordination and integration, and health maintenance,
counseling, and/or patient education. The clinicians were often a patient’s first
point of contact for the health system with some degree of longitudinal
responsibility for the patient. This definition was used to reach out to country
experts and identify who is considered a primary care clinician in each
respective country. National workforce data or Eurostat data, where available,
was then categorized according to expert responses. Physicians specializing in
obstetrics and gynecology are categorized as specialists for all countries but
have their own category in this figure.
Clinical Review & Education Special Communication Health Care Spending in the United States and Other High-Income Countries
1032 JAMA March 13, 2018 Volume 319, Number 10 (Reprinted) jama.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a London School of Economics User  on 03/14/2018
whereas for breast screening, Medicare beneficiaries had the high-
est rates (82%). Conversely, Medicare beneficiaries had the highest
rates of mortality for both ischemic stroke and acute myocardial
infarction. There was also variability in avoidable admissions:
patients with Medicaid insurance had the highest number of
asthma-related admissions and Medicare beneficiaries had the
highest number of admissions for diabetes. When disaggregated
by income or race, life expectancy was significantly different
among US groups, with nonwhite and poorer populations having
shorter life expectancies (eTables 3 and 4 in Supplement 1).
Equity
The United States had the highest horizontal inequity, indicating
the most inequitable access to physicians when adjusted for need. The
United States had an 11% rate of out-of-pocket spending as a percent-
age of total national health spending (compared with a mean of
13% in all 11 countries) and a 2.6% rate as a percentage of house-
hold consumption (compared with a mean of 2.4%) (Figure 11 and
eTable 7 in Supplement 2). However, the United States had a higher
proportion of unmet need in the population, with 22.3% of the popu-
lation reporting that they missed a consultation because of cost com-
pared with the mean of 9.4% for all 11 study countries. Given that the
system has free access at the point of entry, the United Kingdom re-
ported one of the lowest levels of barriers to accessing health ser-
vices, but the level was higher than in both Germany and Sweden.
Discussion
In this study based on data primarily from 2013-2016, the United
States spent approximately twice as much as other high-income
countries on medical care and fared worse on common population
health outcomes such as life expectancy and infant mortality. How-
ever, the main findings of this comparison were that, contrary to
some explanations for high spending, US social spending and health
care utilization were relatively similar to other high-income na-
tions. Although utilization of some surgical procedures (such as coro-
nary angioplasty, total knee replacement, and cesarean delivery) was
higher in the United States, this utilization did not appear to ex-
plain a large part of the higher spending in the United States.
Figure 7. Utilization
Discharges per 100 000 population
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NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands. See eTable 4 in Supplement 2 for data ordered by country.
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The data also suggest that some of the more common explana-
tions about higher health care spending in the United States,
such as underinvestment in social programs, the low primary
care/specialist mix, the fee-for-service system encouraging high
volumes of care, or defensive medicine leading to overutilization,
did not appear to be major drivers of the substantially higher US
health care spending compared with other high-income countries.
Instead, the data suggest that the main driving factors were
likely related to prices, including prices of physician and hospital
services, pharmaceuticals, and diagnostic tests, which likely also
affected access to care. In addition, administrative costs appeared
much higher in the United States. These findings indicate that
efforts targeting utilization alone are unlikely to reduce the gap in
spending between the United States and other high-income coun-
tries, and a more concerted effort to reduce prices and administra-
tive costs is likely needed.
Several findings in this report may be surprising to policy mak-
ers. There is broad consensus among US policy makers that the
United States spends too much on health services and too little on
social services. This analysis showed that US social spending ap-
pears to be similar to that in other high-income OECD countries. This
finding calls into question the belief that higher health care spend-
ing is due to a lack of investment in social determinants. In particu-
lar, given that the United States did not appear to be an outlier with
regard to utilization of services, it is unlikely that a lack of social spend-
ing results in higher health care spending due to a misallocation of
resources that results in greater need (and overutilization).
Another common perception among policy makers is that the
US system is often perceived to be disproportionately driven by
specialist care. However, the number of specialist practitioners in
the US system, both as an absolute number and a percentage, was
not considerably different from comparison countries. One expla-
nation may be differences in the way primary care services are
delivered in other countries. In many other countries, nurses and
allied health professionals may make up a higher proportion of the
health care workforce,21 although we did not find substantially
higher numbers of nurses in the other countries. The extent to
which this explains variation in numbers of physicians across sys-
tems is unclear, but it is unlikely to fully account for why the United
States is not an outlier.
Although the ratio of primary care physicians to specialists was
similar between the United States and other high-income countries,
Figure 8. Performance on Key Measures of Utilization
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The vertical dashed lines indicate mean values.
a Consultations is the mean number of consultations or visits with a physician per person per year in all care delivery settings.
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the salaries paid to both generalist and specialist physicians were
markedly higher in the United States, where specialists were paid
twice as much as those in the United Kingdom or Germany and pri-
mary care physicians and nurses also had substantially higher sala-
ries. However, it can be difficult to compare salaries of workers from
various countries. In general, salaries for professionals are higher in
the United States than in other countries, and in addition, workers
in the United States bear higher costs in some areas, such as for health
care insurance, higher education, or planning for retirement, than
workers in other countries. Some of these issues are accounted for
in the ratio of national average wage, but US physicians and nurses
still had the highest ratio.
Some of the differential observed in cost between physicians
and nurses in the United States and in the other countries may re-
flect differences in productivity or the extent to which training costs
are borne by the individual, although in either case it is unlikely to
account for the magnitude of the difference. In 2011, Laugesen and
Glied19 estimated that the investment repayment cost for private
education in the United States would amount to about $21 300 per
year for a primary care physician and about $24 400 for an ortho-
pedic surgeon over a 35-year period.
Taking this investment into account, however, does not explain
the more than $200 000 difference in compensation observed for
physicians between countries. Although remuneration varies widely
across systems, the optimal level of compensation remains unclear.
Salaries in the United States may be high, but recent debates on re-
muneration of medical staff in the United Kingdom and France, for
example, suggest that salaries in other countries may be too low.22
Other indicators, such as average wages for competitive nonhealth
professions or retention of medical graduates, may help inform ap-
propriate salaries of health care professionals in a given country.
Prices of services were not examined directly, but US health
care spending was found to be higher than in other countries
despite similar utilization patterns, suggesting that higher prices
were the primary cause of high health care spending in the United
States relative to other nations. This is consistent with prior work
Figure 9. Pharmaceuticals
Rank (highest to lowest) 1 2 3 4 5 6 7 8 9 10 11 Mean
Retail pharmaceutical spending




















































































































































































































































































































NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands.
See eTable 5 in Supplement 2 for data ordered by country.
a US discounted prices are listed; nondiscounted prices are $216.00 for Crestor,
$372.75 for long-acting insulin, $309.60 for Advair, and $3430.82 for Humira.
b A new chemical entity is a compound without any precedent among the
regulated and approved drug products.
c Volume is most often the proportion of total prescriptions that were for
generic brands. Volumes can be expressed in defined daily doses or as a
number of packages/boxes or standard units. Value is most often the
proportion of total cost (ie, government and patient expenditure) that was for
generic brands. Values can be, for instance, the turnover of pharmaceutical
companies, the amount paid for pharmaceuticals by third-party payers, or the
amount paid by all payers (third-party and consumers). Market value is most
often at ex-factory prices, while amounts paid by third-party payers and
consumers are in general at retail prices.
d Defined daily dose is the assumed mean maintenance dose per day for a drug
used for its main indication in adults. Data shown here are actual mean defined
daily doses for each country.
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by Anderson et al,23 which also illustrated higher health care
spending in the United States despite similar inputs and levels of
care utilization, and more recent work by Dieleman et al.13 In addi-
tion to differential prices for physician services and pharmaceuti-
cals, these results suggest that prices for nonphysician services and
procedures also appeared to be markedly higher in the United
States. For the select procedures for which comparable data were
available, the United States paid considerably more than its coun-
terparts. In 2013, the International Federation of Health Plans24
reported that the average cost in the United States was $75 345
for a coronary artery bypass graft surgery, whereas the costs
in the Netherlands and Switzerland were $15 742 and $36 509,
respectively. Computed tomography was also much higher in the
United States, with an average payment of $896 per scan com-
pared with $97 in Canada, $279 in the Netherlands, $432 in Swit-
zerland, and $500 in Australia in 2013. Similarly, the mean payment
for an MRI in the United States was $1145 compared with $350 in
Australia and $461 in the Netherlands.
Of particular interest to US health policy makers is the role of
the pharmaceutical market and its influence on health care spend-
ing. Not surprisingly, US spending on pharmaceuticals was almost
double the spending in comparison countries. Previous work sug-
gests that this is driven by high prices for brand-name drugs rather
than by utilization, which is comparable with other high-income
countries.24-27 Across comparison countries, the United States had
the highest volume of generics, accounting for more than 80% of
Figure 10. Access and Quality
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NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands.
See eTable 6 in Supplement 2 for data ordered by country.
a Able to get same- or next-day appointment when sick, excluding those who
did not need to see a physician or nurse.
b Women aged 40 to 49 years in Sweden.
c Thirty-day stroke mortality after hospital admission for ischemic stroke.
d Limited to a primary diagnosis of diabetes.
e Diabetes hospitalizations are limited to persons aged 15 years or older, whereas
the denominator (population with diabetes) is both adult and pediatric.
f Limited to a primary diagnosis of asthma.
g Asthma hospitalizations are limited to persons aged 15 years or older, whereas
the denominator (population with asthma) is both adult and pediatric.
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total pharmaceuticals used by US residents yet just under 30% of
the United States’ total spending on pharmaceuticals. Australia and
France had much smaller generic market penetration rates, presum-
ably because brand-name drugs are comparatively affordable.25
Although the United States’ high prices of pharmaceuticals are
controversial, these prices have been viewed as critical to innova-
tion, including US production of new chemical entities.18,28 Whether
innovation justifies high levels of spending is not clear.
Performance on access is also a central concern to policy mak-
ers. These data indicated that the United States had the lowest rate
of insurance coverage. However, the percentage of the population
with health insurance is at a historical high and has continued to in-
crease since the passage of the Affordable Care Act. Out-of-pocket
spending was also surprisingly low in the United States, which may
be explained in part by the relatively high proportion of patients who
do not seek care or who skip consultations because of high costs.
Prior work has shown that out-of-pocket spending is more concen-
trated among the poor.29 Other factors influencing access to care
in the United States aside from affordability likely include the coun-
try’s considerable landmass (and correspondingly large rural popu-
lation). Personal choice is an additional albeit contentious factor. For
example, the Kaiser Family Foundation has found that approxi-
mately 20% of uninsured US residents have incomes of 400% or
more of the federal poverty level and have largely chosen to forgo
insurance.30 In the other countries in this study with similar health
insurance designs (the Netherlands and Switzerland), the propor-
tion of the population choosing to forego coverage is considerably
less.31,32 Still, a substantial proportion of people would benefit from
coverage but remain uninsured in the United States, and increas-
ing coverage for these individuals remains a policy priority.
A central concern in the United States is the extent to which
greater health care spending translates to better outcomes. Com-
paring intermediate country-level health care outcomes across a
range of health care services showed that the United States does
perform favorably on certain acute care outcomes but less so for
primary care measures. Notably, the United States had among the
highest breast cancer screening rates and the lowest 30-day mor-
tality rates for acute myocardial infarction and stroke. Although the
rates of avoidable hospitalizations in the United States, such as for
diabetes and asthma, are well above those of most of the countries
in the analysis, accounting for the United States’ higher prevalence
of both diseases reduced this gap considerably. The United States
has relatively poor population health outcomes, which likely repre-
sents a combination of factors including issues with the affordabil-
ity of care. However, the United States average, in comparison
to averages of much smaller, more homogeneous countries, may
lead to erroneous conclusions. For example, the life expectancy of
Minnesota, a state comparable in size and demographics to
Figure 11. Distribution and Equity
Out-of-pocket spending
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NA indicates not applicable. CHE indicates Switzerland; NLD, the Netherlands.
See eTable 7 in Supplement 2 for data ordered by country.
a The horizontal inequity index is the percentage probability of a physician visit
in the past 12 months by wealth. If the index is greater than 0, then
high-income groups access physicians more than low-income groups after
adjustment for relative need.
b Regarding unmet need, the Commonwealth Fund International Health Policy
Survey poses a number of questions to a representative sample from each
country. For this indicator, it was analyzed whether a respondent did not
consult with or visit a physician because of cost, skipped a medical test,
treatment, or follow-up that was recommended by a physician because of
cost, or did not fill or collect a prescription for medicine or skipped doses
of medicine because of cost. Low income is defined as household income
less than 50% of the country median.
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Sweden or Denmark, has more similar population health outcomes
to these countries than Minnesota has in comparison to Mississippi.
This analysis extends to a body of work that has explored US
health care spending33 by revisiting comparisons following the pas-
sage of the Affordable Care Act, which has both increased cover-
age and spurred health care delivery reform toward the delivery of
high-value care.9,13 Similar to previous work by Garber and Skinner,10
Reinhardt et al,12 and Anderson et al23 that examined US health care
spending relative to other OECD countries, we found that the United
States spent significantly more on health care despite having simi-
lar levels of utilization. However, from 2010 onward it appeared that
the United States had similar levels of public social spending com-
pared with other high-income countries. While public social spend-
ing has increased since 2010 (from 15.6% of GDP in 2005 to 19.3%
of GDP in 2010), utilization rates have remained relatively
unchanged.20,23 This finding suggests that differences in social
spending are less likely to be the main driver of differences in health
care spending than previous works have suggested.34 This is a simi-
lar conclusion to recent work by Dieleman et al,13 which identified
prices and intensity of care to be largely related to increases in health
care spending over the past 15 years and negatively associated with
disease prevalence or incidence.
This study has several limitations. First, there was limited avail-
ability of comparable data across health systems, which restricted
the areas of health system performance we were able to compare.
In particular, data on prices across systems were lacking, as was the
number of indicators on quality and coverage. The indicators se-
lected thus provide a snapshot of performance in some domains—
particularly quality—which may not be representative of quality of
the entire system or may be limited due to data availability across
all countries. For instance, 30-day mortality rates reflect only in-
hospital rates, which may influence the apparent variations ob-
served, particularly given differences in length of stay and dis-
charge practices across countries. Second, because of the difficulties
in collecting and standardizing indicators across countries, some of
the data used reflect different years, may be out of date, or may have
been measured differently based on country-specific definitions of
variables. Even when data were collected from the same source, is-
sues of comparability remain because of fundamental differences
in how systems are organized and, in turn, how care is categorized.
Two areas of particular concern are outpatient spending and the pri-
mary care workforce. We attempted to address limitations in the
workforce data by utilizing a functionality-based approach to iden-
tifying who provides primary care services in each country and by
cross-referencing resulting numbers with country experts. Third, the
study was able to present only descriptive comparative findings, and
it is not possible to make any causal inferences. Fourth, the data did
not adjust for factors such as underlying population differences or
system delivery and organizational factors, which likely influence
some of the observed variation in this space. Fifth, the response rate
to some surveys that were the basis for some measures, such as abil-
ity to get same- or next-day appointment and 2-month wait time to
see a specialist physician, were not good across all countries. Sixth,
we did not consider the actual prices of devices, which, given the
increasing number of hip and knee replacements and use of other
devices, are emerging as an important consideration in the cost of
care in the United States.
Conclusions
The United States spent approximately twice as much as other
high-income countries on medical care, yet utilization rates in the
United States were largely similar to those in other nations. Prices
of labor and goods, including pharmaceuticals, and administrative
costs appeared to be the major drivers of the difference in overall
cost between the United States and other high-income countries.
As patients, physicians, policy makers, and legislators actively
debate the future of the US health system, data such as these are
needed to inform policy decisions.
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